Search

A recent study conducted in Lyon, France, has found that the drug selpercatinib effectively treats existing central nervous system (CNS) disease and prevents or delays the formation of new CNS metastases in patients with RET fusion-positive non-small cell lung cancer (NSCLC). The study analyzed serial CNS scans from a randomized phase III trial and found that the cumulative incidence of CNS progression was reduced with selpercatinib compared to chemotherapy plus pembrolizumab. These results highlight the importance of identifying RET fusions in first-line NSCLC patients and treating them with selpercatinib. The research has been peer-reviewed and published in the Journal of Clinical Oncology. [Extracted from the article]

Researchers at the Center Leon Berard in Lyon, France have conducted a study on targeting HER2 in metastatic gastroesophageal adenocarcinomas. The study highlights the biologically heterogeneous nature of gastric and esophageal adenocarcinomas and the significance of HER2 overexpression in these cases. The development of anti-HER2 therapies, such as trastuzumab, has shown improvements in response rate and survival in patients with metastatic, HER2-positive gastroesophageal adenocarcinomas. The study also discusses the potential additive effect of combining anti-HER2 therapies with immune checkpoint inhibitors and the promising results of new HER2 inhibitors. The research provides a review of recent data and perspectives in HER2-positive metastatic gastroesophageal adenocarcinomas. [Extracted from the article]

Keywords: Lyon; France; Europe; Adalimumab Therapy; Antirheumatics; Biotechnology; Drugs and Therapies; Eye Diseases and Conditions; Health and Medicine; Immunologic Agents; Monoclonal Antibodies; Ophthalmology; Pharmaceuticals; Tumor Necrosis Factor (TNF) Inhibitors; Uveal Diseases and Conditions; Uveitis EN Lyon France Europe Adalimumab Therapy Antirheumatics Biotechnology Drugs and Therapies Eye Diseases and Conditions Health and Medicine Immunologic Agents Monoclonal Antibodies Ophthalmology Pharmaceuticals Tumor Necrosis Factor (TNF) Inhibitors Uveal Diseases and Conditions Uveitis 2125 2125 1 10/30/23 20231031 NES 231031 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators discuss new findings in Eye Diseases and Conditions - Uveitis. According to the news editors, the research concluded: "TDM of ADA treatment proved relevant to provide CNIU patients with a personalised and optimised treatment course (in terms of frequency and type of drug).". [Extracted from the article]

Keywords: Lyon; France; Europe; Antineoplastic Monoclonal Antibodies; Antineoplastics; Bevacizumab Therapy; Cancer; Carcinomas; Chemotherapy; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Etoposide; Etoposide Therapy; Health and Medicine; Immunologic Agents; Mitotic Inhibitors; Monoclonal Antibodies; Naphthalenes; Neuroendocrine Cancer; Oncology; Pharmaceuticals; Podophyllotoxin; Tyrosine Kinase Inhibitors; VEGF - VEGFR Inhibitors; VEGFR Inhibitors EN Lyon France Europe Antineoplastic Monoclonal Antibodies Antineoplastics Bevacizumab Therapy Cancer Carcinomas Chemotherapy Clinical Research Clinical Trials and Studies Drugs and Therapies Etoposide Etoposide Therapy Health and Medicine Immunologic Agents Mitotic Inhibitors Monoclonal Antibodies Naphthalenes Neuroendocrine Cancer Oncology Pharmaceuticals Podophyllotoxin Tyrosine Kinase Inhibitors VEGF - VEGFR Inhibitors VEGFR Inhibitors 1187 1187 1 04/24/23 20230425 NES 230425 2023 APR 24 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- A new study on Oncology - Neuroendocrine Cancer is now available. Researchers' Work from University Hospital of Lyon Focuses on Neuroendocrine Cancer [Bevacizumab Plus Folfiri After Failure of Platinum- Etoposide First-line Chemotherapy In Patients With Advanced Neuroendocrine Carcinoma (Prodige 41-bevanec):...] According to news originating from Lyon, France, by NewsRx correspondents, research stated, "There is no standard second-line treatment after platinum-etoposide chemotherapy for gastroenteropancreatic neuroendocrine carcinoma. [Extracted from the article]

Keywords for this news article include: Lyon, France, Europe, Amino Acid Receptors, Antibodies, Ataxia, Autoimmunity, Blood Proteins, Brain Diseases and Conditions, Central Nervous System Diseases and Conditions, Cerebellar Ataxia, Cerebellar Diseases and Conditions, Drugs and Therapies, Dyskinesias, Glutamate Receptors, Glutamates, Glutamic Acid, Health and Medicine, Immunoglobulins, Immunology, Immunotherapy, Membrane Proteins, Nervous System Diseases and Conditions, Neurologic Manifestations, Neurology, Proteins, University Hospital of Lyon. Keywords: Lyon; France; Europe; Amino Acid Receptors; Antibodies; Ataxia; Autoimmunity; Blood Proteins; Brain Diseases and Conditions; Central Nervous System Diseases and Conditions; Cerebellar Ataxia; Cerebellar Diseases and Conditions; Drugs and Therapies; Dyskinesias; Glutamate Receptors; Glutamates; Glutamic Acid; Health and Medicine; Immunoglobulins; Immunology; Immunotherapy; Membrane Proteins; Nervous System Diseases and Conditions; Neurologic Manifestations; Neurology; Proteins EN Lyon France Europe Amino Acid Receptors Antibodies Ataxia Autoimmunity Blood Proteins Brain Diseases and Conditions Central Nervous System Diseases and Conditions Cerebellar Ataxia Cerebellar Diseases and Conditions Drugs and Therapies Dyskinesias Glutamate Receptors Glutamates Glutamic Acid Health and Medicine Immunoglobulins Immunology Immunotherapy Membrane Proteins Nervous System Diseases and Conditions Neurologic Manifestations Neurology Proteins 1031 1031 1 04/03/23 20230404 NES 230404 2023 APR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- A new study on Central Nervous System Diseases and Conditions - Cerebellar Ataxia is now available. [Extracted from the article]

Lyon, France, Europe, Antibodies, Autoantibodies, Blood Proteins, Health and Medicine, Immunology, Immunoproteins, Lymphatic Diseases and Conditions, Proteins, Serum Globulins, Thymoma, Thymus Neoplasms Keywords: Lyon; France; Europe; Antibodies; Autoantibodies; Blood Proteins; Health and Medicine; Immunology; Immunoproteins; Lymphatic Diseases and Conditions; Proteins; Serum Globulins; Thymoma; Thymus Neoplasms EN Lyon France Europe Antibodies Autoantibodies Blood Proteins Health and Medicine Immunology Immunoproteins Lymphatic Diseases and Conditions Proteins Serum Globulins Thymoma Thymus Neoplasms 613 613 1 03/23/23 20230320 NES 230320 2023 MAR 24 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Lymphatic Diseases and Conditions - Thymoma have been published. [Extracted from the article]